Novo Nordisk (NVO) stock is down sharply after releasing topline results from its 2-year evoke and evoke+ phase 3 Alzheimer’s trials. • Premarket: ~$42.68 • Down: ~10% • Previous close: ~$47.63 The trials enrolled 3,808 adults with early-stage symptomatic Alzheimer’s and tested oral semaglutide versus placebo. While biomarkers improved, the treatment did not slow disease progression on the key CDR-SB cognitive scale. Novo is discontinuing the planned 1-year extension for both studies. Semaglutide remained safe and well tolerated, and Novo cites more than 37 million patient-years of exposure across diabetes and obesity settings. Full article: benzinga.com/news/25/11/49028150/novo-nordisks-blockbuster-weight-loss-drug-flops-in-alzheimers-trial #nvo #stock #drop 🖥️ Try Benzinga Pro FREE with a 14 day trial: benzinga.com/pro/register 📈 Take your trading to the next level with our suite of premium research services and tools: benzinga.com/servic...